Estrogen replacement therapy and risk of epithelial ovarian cancer

Gynecologic Oncology

Volumn 63, Issue 2, 1996, Pages 254-257

  Risch, Harvey A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER RISK; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0030298050     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0315     Document Type: Article

References (21)

1. 1. Whittemore, A. S., Harris, R., Itnyre, J., and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women, Am. J. Epidemiol. 136, 1184-1203 (1992).
2. 2. Risch, H. A., Marrett, L. D., and Howe, G. R. Parity, contraception, infertility, and the risk of epithelial ovarian cancer, Am. J. Epidemiol. 140, 585-597 (1994).
3. 3. Tzonou, A., Day, N. E., Trichopoulos, D., Walker, A., Saliaraki, M., Papapostolou, M., and Polychronopoulou, A. The epidemiology of ovarian cancer in Greece: A case-control study, Eur. J. Cancer Clin. Oncol. 20, 1045-1052 (1984).
4. 4. Booth, M., Beral, V., and Smith, P. Risk factors for ovarian cancer: A case-control study, Br. J. Cancer 60, 592-598 (1989).
5. 5. Polychronopoulou, A., Tzonou, A., Hsieh, C.-C., Kaprinis, G., Rebelakos, A., Toupadaki, N., and Trichopoulos, D. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer, Int. J. Cancer 55, 402-407 (1993).
6. 6. Annegers, J. F., Strom, H., Decker, D. G., Dockerty, M. B., and O'Fallon, W. M. Ovarian cancer: Incidence and case-control study, Cancer 43, 723-729 (1979).
7. 7. Kaufman, D. W., Kelly, J. P., Welch, W. R., Rosenberg, L., Stolley, P. D., Warshauer, M. E., Lewis, J., Woodruff, J., and Shapiro, S. Noncontraceptive estrogen use and epithelial ovarian cancer, Am. J. Epidemiol. 130, 1142-1151 (1989).
8. 8. Weiss, N. S., Lyon, J. L., Krishnamurthy, S., Dietert, S. E., Liff, J. M., and Daling, J. R. Noncontraceptive estrogen use and the occurrence of ovarian cancer, J. Natl. Cancer Inst. 68, 95-98 (1982).
9. 9. Cramer, D. W., Hutchison, G. B., Welch, W. R., Scully, R. E., and Ryan, K. J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history, J. Natl. Cancer Inst. 71, 711-716 (1983).
10. 10. Parazzini, F., La Vecchia, C., Negri, E., and Villa, A. Estrogen replacement therapy and ovarian cancer risk, Int. J. Cancer 57, 135-136 (1994).
11. 11. Rodriguez, C., Calle, E. E., Coates, R. J., Miracle-McMahill, H. L., Thun, M. J., and Heath, C. W., Jr. Estrogen replacement therapy and fatal ovarian cancer, Am. J. Epidemiol. 141, 828-835 (1995).
12. 12. Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., and Quinn, M. Estrogen replacement therapy and risk of epithelial ovarian cancer, Am. J. Epidemiol. 143, S43 (1996).
13. 13. Risch, H. A., Marrett, L. D., Jain, M., and Howe, G. R. Differences in risk factors for epithelial ovarian cancer by histologic type: Results of a case-control study, Am. J. Epidemiol. 144, 363-372 (1996).
14. 14. Statistics Canada. 1991 Census of Canada, the nation: Fertility, Minister of Industry, Science and Technology, Ottawa (1993).
15. 15. Hart, W. R. Pathology of malignant and borderline (low malignant potential) epithelial tumors of ovary, in Gynecologic oncology: Fundamental principles and clinical practice, 2nd ed. (M. Coppleson, Ed.), Churchill Livingstone, Edinburgh, Vol. 2, pp. 863-887 (1992).
16. 16. Harlow, B. L., Weiss, N. S., Roth, G. J., Chu, J., and Daling, J. R. Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones, Cancer Res. 48, 5849-5852 (1988).
17. 17. Hartge, P., Hoover, R., McGowan, L., Lesher, L., and Norris, H. J. Menopause and ovarian cancer, Am. J. Epidemiol. 127, 990-998 (1988).
18. 18. Folsom, A. R., Mink, P. J., Sellers, T. A., Hong, C. P., Zheng, W., and Potter, J. D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women, Am. J. Public Health 85, 1128-1132 (1995).
19. 19. Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., and Cummings, S. R. Estrogen replacement therapy and fractures in older women, Ann. Intern. Med. 122, 9-16 (1995).
20. 20. Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., and Speizer, F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women, N. Engl. J. Med. 332, 1589-1593 (1995).
21. 21. Stampfer, M. J., and Colditz, G. A. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence, Prev. Med. 20, 47-63 (1991).